NCT00051571已完成2 期
A Phase II Study Using SGN-15 (cBR96-Doxorubicin Immunoconjugate) in Combination With Docetaxel for the Treatment of Advanced Stage or Recurrent Non-Small Cell Lung Carcinoma
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- Seagen Inc.
- 入组人数
- 60
- 试验地点
- 18
研究概览
简要总结
This randomized phase II clinical trial evaluates the combination of a monoclonal antibody-based drug (SGN-15) with a chemotherapeutic agent compared to chemotherapy given alone in patients with non-small cell lung cancer that has failed at least one prior systemic therapy. The objective of the study is to determine the safety and clinical benefit, as measured by tumor response and quality of life, to the combination regimen.
Monoclonal antibody therapy has been used in other types of cancer to target therapy to the tumor, thereby allowing for the chemotherapeutic agent to have a lesser effect on normal, healthy tissue.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with pathologically confirmed NSCLC which is metastatic or recurrent (non-resectable), who have failed at least one but no more than two prior therapies for advanced stage disease or have a recurrence within 6 months of completing adjuvant chemotherapy.
- •Lewis-y antigen expression documented by immunohistochemistry for all patients.
- •Patients must have:
- •Bidimensionally or unidimensionally measurable disease on the basis of physical exam or imaging studies, or
- •Evaluable disease: bone metastases defined on bone scan or malignant pleural effusion
- •Performance status ≤ 2 (ECOG scale) with a life expectancy of at least 3 months
- •Patients must be at least four weeks from prior treatment (chemotherapy, hormonal therapy, or definitive radiotherapy)
排除标准
- •Prior therapy with TAXOTERE (docetaxel)
- •Cumulative anthracycline exposure > 300 mg/m
- •More than one primary malignancy with the exception of:
- •Non-melanoma skin cancer
- •In situ carcinoma of the cervix
- •Localized prostate cancer
- •Completely resected stage I or II disease with no evidence of recurrent cancer from which the patient has remained disease free for more than 3 years.
- •Uncontrolled significant non-malignant disease (e.g. congestive heart failure, bleeding, renal failure, hepatic failure).
- •Uncontrolled, symptomatic brain metastasis.
- •Peripheral neuropathy > grade
- •Concomitant therapy with other anti-neoplastic agents or experimental agents except for small volume radiation to a solitary bony metastasis.
- •Active viral, bacterial or systemic fungal infections including known HIV or Hepatitis B or C.
- •Women who are pregnant or breastfeeding
- •Any serious underlying medical condition, which would impair the ability of the patient to receive the planned treatment including prior allergic reactions to recombinant human or murine proteins.
- •Dementia or altered mental status that would prohibit the understanding and rendering of informed consent.
- •Patients with uncontrolled peptic ulcer disease will be excluded.
研究者
研究点 (18)
Loading locations...
相似试验
终止
2 期
Safety/Efficacy Study of SGN-15 (Antibody-Drug Conjugate) Combined With Gemcitabine in Patients With Ovarian CancerOvarian NeoplasmsNCT00051584Seagen Inc.60
已完成
2 期
Study of SGN-15, Antibody-Drug Conjugate, to Treat Hormone Refractory Prostate CancerProstatic NeoplasmsNCT00031187Seagen Inc.160
招募中
2 期
NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) TrialNeuroblastomaNCT06450041New Approaches to Neuroblastoma Therapy Consortium62
已完成
2 期
Efficacy, Pharmacokinetics, Safety, and Immunogenicity Study of Abatacept Administered Subcutaneously to Treat Rheumatoid Arthritis in Japanese PatientsRheumatoid ArthritisNCT01001832Bristol-Myers Squibb118
已完成
2 期
Efficacy and Safety Study of KN019 in Rheumatoid Arthritis Patients With an Inadequate Response to MethotrexateRheumatoid ArthritisNCT04038970Jiangsu Alphamab Biopharmaceuticals Co., Ltd145